

ARTICLE

COMP mutation screening as an aid for the clinical diagnosis and counselling of patients with a suspected diagnosis of pseudoachondroplasia or multiple epiphyseal dysplasia

Jason Kennedy¹, Gail Jackson^{1,2}, Simon Ramsden¹, Jacky Taylor¹, William Newman³, Michael J Wright⁴, Dian Donnai³, Rob Elles¹ and Michael D Briggs^{*,2}

¹National Genetics Reference Laboratory (Manchester), Regional Genetics Services, St. Mary's Hospital, Manchester, UK; ²Wellcome Trust Centre for Cell-Matrix Research, Faculty of Life Sciences, University of Manchester, Manchester, UK; ³Medical Genetics, St Mary's Hospital, Manchester, UK; ⁴Institute of Human Genetics, International Centre for Life, Newcastle-upon-Tyne, UK

The skeletal dysplasias are a clinically and genetically heterogeneous group of conditions affecting the development of the osseous skeleton and fall into the category of rare genetic diseases in which the diagnosis can be difficult for the nonexpert. Two such diseases are pseudoachondroplasia (PSACH) and multiple epiphyseal dysplasia (MED), which result in varying degrees of short stature, joint pain and stiffness and often resulting in early onset osteoarthritis. PSACH and some forms of MED result from mutations in the cartilage oligomeric matrix protein (COMP) gene and to aid the clinical diagnosis and counselling of patients with a suspected diagnosis of PSACH or MED, we developed an efficient and accurate molecular diagnostic service for the COMP gene. In a 36-month period, 100 families were screened for a mutation in COMP and we identified disease-causing mutations in 78% of PSACH families and 36% of MED families. Furthermore, in several of these families, the identification of a disease-causing mutation provided information that was immediately used to direct reproductive decision-making.

European Journal of Human Genetics (2005) 13, 547–555. doi:10.1038/sj.ejhg.5201374

Published online 9 March 2005

Keywords: Skeletal dysplasia; cartilage oligomeric matrix protein; gene mutation; molecular diagnosis

Introduction

The osteochondrodysplasias are a clinically and genetically heterogeneous group of conditions affecting the development of the osseous skeleton. Over 200 unique phenotypes have been described and subsequently grouped into 33 distinct diagnostic groups by the International Working

group on the Classification of Constitutional Disorders of Bone¹. Although individually rare, the skeletal dysplasias have an overall birth prevalence of at least 3.9 per 10 000^{2–6} and based on a European population of 375 million, there are at least 150 000 individuals in the EU who have a recognised bone dysplasia.

The osteochondrodysplasias fall into the category of rare genetic disease and/or condition in which the diagnosis can be difficult. The clinical diagnosis of a specific skeletal dysplasia usually involves several types of investigation such as family history, physical examination and, most importantly, a comprehensive radiographic evaluation.⁷ Arriving at the correct clinical diagnosis is essential because

*Correspondence: Dr Michael D Briggs, Wellcome Trust Centre for Cell Matrix Research, Faculty of Life Sciences, University of Manchester, Michael Smith Building, Oxford Road, Manchester, M13 9PT, UK.
Tel: +44 161 275 5642; Fax: +44 161 275 5082;

E-mail: mike.briggs@man.ac.uk

Received 12 October 2004; revised 30 November 2004; accepted 8 December 2004

there are a number of complications associated with bone dysplasias. These may be, for example, orthopaedic,⁸ neurologic,^{8,9} cardiorespiratory^{10,11} or psychological^{12–14} in nature and are often predictable and either preventable or treatable.^{8,15} Importantly, many complications are diagnosis specific and molecular analysis plays a valuable role not only in establishing a diagnosis and facilitating accurate risk estimation and genetic counselling but also in assisting in clinical management of the condition.¹⁶

Pseudoachondroplasia (PSACH) and multiple epiphyseal dysplasia (MED) belong to the same diagnostic group and comprise a clinical spectrum ranging from mild MED phenotypes to typical severe PSACH.¹⁷ They are characterised by various degrees of disproportionate short stature, lower limb deformities and early onset osteoarthritis. PSACH results exclusively from mutations in the gene encoding cartilage oligomeric matrix protein (COMP), a large pentameric glycoprotein found in cartilage tendon and ligament. The more severe forms of MED are allelic with PSACH and can also result from COMP mutations; however, MED is genetically heterogeneous and milder forms can result from mutations in the genes encoding type IX collagen and matrilin-3.¹⁸ Although disease-specific molecular diagnostic methods for PSACH and MED have been developed, links from this basic research to applied clinical research are not well established.¹⁹ We therefore established an accurate and efficient molecular diagnostic service for the COMP gene. In a 36-month period (June 2001–May 2004), 100 families were referred with a suspected diagnosis of PSACH or MED and we identified a COMP mutation in 53 of these families. In seven of these families, the identification of a disease-causing mutation not only confirmed the clinical diagnosis of a bone dysplasia, but also provided information that has been subsequently used to direct reproductive decision-making and allow testing of at-risk family members.

Materials and methods

Genomic DNA was received in Manchester for our ongoing studies as part of the UK Collaborative Study of Genetic Diagnosis for Skeletal Dysplasias and the European Skeletal Dysplasia Network (www.esdn.org). In each case, a diagnosis of PSACH or MED was suspected on the clinical and radiographic presentation of the proband and other affected family members. The University of Manchester Ethical Committee approved this study and informed consent was obtained from all individuals.

PCR amplification of exons 8–19, including the immediate splice donor and acceptor sites of the COMP gene was performed using exon-specific intronic primers (Table 1) in eight separate PCR amplicons. Briefly, PCR amplifications were performed in a total volume of 40 μ l using a custom PCR ReddyMix™ master mix (ABgene, UK) containing

Table 1 Primer sequences for PCR amplification of exons 8–19 of the COMP gene

Primer Sequence (5' → 3')	Annealing temperature (°C)	Product size (bp)
8F TTG AGG CGG GGT TGG GTG	64	413
9R ACC GTG CCG AGC CGT AGA T		
10F AGG AGT GTG ACC TTT GCC TTC T	64	334
10R CTA GTC CAG CTT ACC CCA TCC		
11F GAA GTC ATT CTG GCC TGG TC	64	518
12R AGC GTT TTG TCA AAG GCT ACC		
13F CGG GTA GCC TTT GAC AAA ACG	62	331
13R GCC CGC CCA CCG TAG AC		
14F GGC GGG CCC TGA CTT TAG	64	546
15R ATA ACC CCG CCC CTC TGT		
16F GTT CTG GGT GCC AGG TTC	64	335
16R AAG GGT TTT ACG GAG GGT CAT		
17F TGC TCC CAA CTG TCT CC CA	64	312
17R ACC TGG GCC TGT GTG TCC		
18F TCT GAG AGG GAA GGG TCT GG	64	443
19R CCC TTC TCA CTT CCC CCT CA		

0.5 μ M of each primer, 1.25 U of *Taq* polymerase, 67 mM Tris-HCl (pH 8.0 at 25°C), 16 mM (NH₄)₂SO₄, 3.7 mM MgCl₂, 0.085 mg/ml BSA, 6.7 μ M EDTA, 0.75 mM of each dNTP and 50–100 ng of genomic DNA. PCR thermal cycling consisted of an initial denaturation at 95°C for 3 min, followed by 35 cycles of denaturation at 94°C for 30 s, annealing (62–64°C depending on the primer annealing temperature) for 30 s, and extension at 72°C for 1 min, followed by a final extension at 72°C for 5 min. PCR amplification was performed in a Dyad Disciple™ thermal cycler (MJ Research® Inc., USA). PCR products were visualised by agarose gel electrophoresis to ensure that amplification had occurred without contamination, then purified using the QuickStep™2 PCR purification system (Edge Biosystems, USA). Purified PCR products were used as a template for bidirectional fluorescent DNA sequencing. To facilitate higher throughput mutation screening, genomic DNA dilutions at 100 ng/ μ l were aliquoted into 96-well plates. Subsequent PCR reactions were set up in 96-well PCR plates (ABgene, UK) using multi-channel pipettes (Anachem, UK). Sequencing reactions were performed with ABI PRISM® BigDye™ Terminators v 2.0 Cycle Sequencing Ready Reaction Kit (Applied Biosystems, UK). DNA sequencing reactions were purified by gel filtration using Sephadex® G-50 (Sigma, UK) loaded Multiscreen-HV plates (Millipore, UK), then electrophoresed on either an ABI PRISM® 3100 Genetic Analyzer (Applied Biosystems, UK) or an Applied Biosystems 3730 XL DNA Analyzer (Applied Biosystems, UK). The DNA sequence data generated were compared against a reference sequence to detect variants using the Staden sequence analysis package.²⁰ All DNA sequence traces were compared with a normal nonaffected control and checked against the published

COMP cDNA sequence (COMP GenBank Accession Number XM_009336).

Results

Patient referrals

Patients with a suspected diagnosis of PSACH or MED were referred to the National Genetics Reference Laboratory (Manchester) as part of one of two studies; 'Meeting the genetic needs of families with skeletal dysplasias' or 'The European Skeletal Dysplasia Network (ESDN)'. In most cases, the referring diagnosis was made by a clinical geneticist and many of these would not have been an expert in the diagnosis of skeletal dysplasias. Furthermore, our own assessment of the available clinical and radiographic information was not a prerequisite for molecular testing.

Development of an accurate and efficient COMP screening protocol

The COMP gene is located on chromosome 19p12 and comprises 19 exons which encode the signal peptide (exon 1), coiled-coil (exons 1–4), type II repeats (exons 4–8), type III repeats (exons 8–15) and C-terminal domain (exons 16–19), respectively.²¹ All of the mutations identified to date in PSACH and MED cluster in the type III or C-terminal domains.¹⁸ We therefore established an accurate and efficient COMP mutation screening protocol by employing bidirectional fluorescent DNA sequencing of exons 8–19 of COMP.

Initially, each exon of COMP (exons 8–19) was individually amplified by PCR and sequenced as 12 separate amplicons in small panels of patients (usually 6–8 patients per panel). Oligonucleotide primers were designed to anneal at the same temperature so that different exons could be amplified by PCR in the same thermal cyclor (Table 1). To improve the turn-round time two exons were amplified as a single amplicon (ie exons 8+9, 11+12, 14+15, 18+19); exons 8–19 of COMP could therefore be amplified and sequenced as eight amplicons. Further improvements included the use of 96-well plates (to amplify different exons for the same panel of patients), in conjunction with multi-channel pipettes for PCR and sequencing and the use of QuickStep 2 PCR-purification system in a 96-well format, which can purify 96 PCRs in one step (to reduce pipetting error and hands-on time). During the course of this study, it was found that panels of 13 patients with the relevant controls samples could be routinely screened (ie 13 patients+one normal control+one mutant control+water control). In total, 16 samples occupied two columns of a 96-well plate and thus in one 96-well plate six PCR amplicons can be analysed for 13 patients.

In all cases, our screening approach consisted of a 'level 1 screen', which involved the analysis of exons 10 and 13,

which were believed to contain the majority of COMP mutations, followed by the analysis of the remaining 10 exons if the level 1 screen proved negative. The detection of individuals who were heterozygous for point mutations was aided by the use of the Staden DNA sequence analysis package.²⁰ Any mutations that we identified were confirmed in a fresh dilution of genomic DNA.

COMP mutational analysis in suspected cases of PSACH or MED

During the course of 3 years, affected and unaffected individuals from 100 families with a skeletal dysplasia were referred to Manchester for COMP analysis (Table 2). This cohort of patients comprised those with a suspected diagnosis of PSACH (45 affected individuals in 41 families), MED (81 affected individuals in 58 families) or SEMD (Hall type)²² (two affected individuals in one family). In this latter family (family 39), the referring clinician requested COMP analysis to rule out a possible diagnosis of PSACH. The majority of families were referred from either the UK ($n=36$) or the rest of Europe ($n=60$), while two cases were referred from Australia and one each from New Zealand and Singapore. Bidirectional fluorescent DNA sequencing of exons 8–19 of COMP was initially performed on the DNA of at least one affected individual from each family and when a potential mutation was identified additional family members were analysed when possible. A potential mutation was defined as an in-frame deletion or insertion or an amino-acid substitution, particularly one that affected a conserved residue within the type III or C-terminal domains of COMP.¹⁸

Sequence analysis of at least one affected individual from the 41 families with a referred diagnosis of PSACH identified disease-causing COMP mutations in 32 (78%) of them, while analysis of the 58 families with a referred diagnosis of MED identified disease-causing COMP mutations in 21 (36%) of these families (Table 2). The only previously published report documenting the frequency of COMP mutations in PSACH and MED found that 100% (25/25) of PSACH²³ and 28% (7/25) of MED²⁴ resulted from COMP mutations. However, this cohort of patients had been preselected following a careful examination of the clinical history and relevant radiographs by the authors (Daniel Cohn, personal communication), which was often not the case with the referrals to our centre. We did not identify a COMP mutation in the single family with SEMD (Hall type) that we analysed, which confirms previous findings.²³

Our inability to detect COMP mutations in 22% of the families referred with a suspected diagnosis of PSACH prompted us to reassess their clinical diagnosis. A clinical history and relevant X-rays were obtained from seven of the nine families, and in six of these families (families 33–35, 38, 41 and 42 in Table 2), a revised diagnosis was suggested, which including spondyloepiphyseal dysplasia

Table 2 Summary of COMP analysis in 100 patients with PSACH, MED or SEMD

Family	No. of family members			Country of referral	Diagnosis on referral	Inheritance	Exon	COMP mutation (nucleotide)	COMP defect (predicted amino-acid change)	Previously published or novel mutation ^a	Differential diagnosis and/or other gene mutation
	A	N	U								
1	2	1	0	UK	PSACH	AD ^b	10	c.1052 G>A	p.Cys351Tyr	Mabuchi <i>et al</i> (2003) ²⁶	
2	1	0	0	F	PSACH	Sporadic?	10	c.1127 A>T	p.Asp376Val	Novel	
3	1	0	0	UK	PSACH	n/d	13	c.1417 G>A	p.Asp473Asn	Deere <i>et al</i> (1998) ²⁷	
4	1	0	0	UK	PSACH	n/d	13	c.1318 G>A	p.Gly440Arg	Loughlin <i>et al</i> (1998) ²⁸	
5	1	0	1	UK	PSACH	AD ^b	13	c.1417_1419 delGAC	p.Asp473 del	Hecht <i>et al</i> (1995) ²⁹	
6	1	0	0	CH	PSACH	n/d	13	c.1318 G>A	p.Gly440Arg	Loughlin <i>et al</i> (1998) ²⁸	
7	1	0	0	CH	PSACH	n/d	13	c.1417_1419 delGAC	p.Asp473 del	Hecht <i>et al</i> (1995) ²⁹	
8	1	0	0	UK	PSACH	n/d	11	c.1170_1181del insTGT	p.Pro391_Asp394del insVal	Loughlin <i>et al</i> (1998) ²⁸	
9	1	0	1	TR	PSACH	AD	9	c.925 G>A	p.Gly309Arg	Delot <i>et al</i> (1998) ³⁰	
10	1	0	0	UK	PSACH	Sporadic	10	c.1021_1026 del	p.Glu341_Asp342 del	Novel	
11	1	2	0	UK	PSACH	Sporadic	14	c.1552 G>A	p.Asp518Asn	Ikegawa <i>et al</i> (1998) ³¹	
12	1	3	0	A	PSACH	Sporadic	14	c.1528_1539 del	p.Ala510_513Val del	Novel	
13	1	2	0	E	PSACH	Sporadic ^c	13	c.1393 G>C	p.Gly465Arg	Novel	
14	1	0	0	D	PSACH	n/d	13	c.1417_1419 delGAC	p.Asp473 del	Hecht <i>et al</i> (1995) ²⁹	
15	1	0	0	D	PSACH	Sporadic ^c	8	c.831_851 del	p.Asp277_Pro283 del	Novel	
16	2	1	0	NZ	PSACH	AD ^b	18	c.2155 G>A	p.Gly719Ser	Novel	
17	1	0	1	UK	PSACH	AD	10	c.1114_1116 del	p.Asp372 del	Briggs <i>et al</i> (1995)	
18	1	0	1	UK	PSACH	AD	13	c.1417_1419 delGAC	p.Asp473 del	Hecht <i>et al</i> (1995) ²⁹	
19	1	0	0	UK	PSACH	n/d	9	c.893 C>T	p.Ser298Leu	Novel	
20	2	0	0	UK	PSACH	AD	14	c.1526 A>G	p.Asp509Gly	Deere <i>et al</i> (1998) ²⁷	
21	1	0	0	D	PSACH	n/d	13	c.1417_1419 delGAC	Asp473 del	Hecht <i>et al</i> (1995) ²⁹	
22	1	0	0	UK	PSACH	AD	13	c.1412 A>G	p.Asp471Gly	Novel	
23	1	0	0	NL	PSACH	n/d	13	c.1417_1419 delGAC	p.Asp473 del	Hecht <i>et al</i> (1995) ²⁹	
24	1	0	0	UK	PSACH	n/d	13	c.1417_1419 delGAC	p.Asp473 del	Hecht <i>et al</i> (1995) ²⁹	
25	1	2	1	I	PSACH	n/d	10	c.1021_1026 del	p.Glu341_Asp342 del	Novel	
26	1	2	0	Singapore	PSACH	Sporadic	13	c.1417_1419 delGAC	p.Asp473 del	Hecht <i>et al</i> (1995) ²⁹	
27	1	0	0	I	PSACH	n/d	13	c.1423 G>A	p.Asp475Asn	Deere <i>et al</i> (1998) ²⁷	
28	1	0	0	G	PSACH	n/d	13	c.1417_1419 delGAC	p.Asp473 del	Hecht <i>et al</i> (1995) ²⁹	
29	1	0	0	F	PSACH	n/d	13	c.1435 G>T	p.Asp479Tyr	Novel	
30	1	0	0	F	PSACH	n/d	14	c.1511 G>C	p.Cys504Ser	Novel	
31	1	0	0	TR	PSACH	n/d	14	c.1586 C>T	p.Thr529Ile	Novel	
32	1	0	0	D	PSACH	n/d	14	c.1553 A>G	p.Asp518Gly	Novel	
33	1	1	0	B	PSACH	n/d			No	SEMD unclassified	
34	1	0	0	UK	PSACH	n/d			No	SEMD/Kniest	
35	2	2	0	G	PSACH	AR or mosaicism			No	SEMD unclassified	
36	1	0	0	UK	PSACH/SMD	n/d			No	SMD unclassified	
37	1	0	0	G	PSACH	AD			No	n/d	
38	1	0	0	UK	PSACH	n/d			No	Brachy C	
39	2	2	0	UK	SEMD	AD			No	SEMD (Hall type) ²²	
40	1	0	0	UK	PSACH	n/d			No	n/d	

Table 2 (Continued)

Family	No. of family members			Country of referral	Diagnosis on referral	Inheritance	Exon	COMP mutation (nucleotide)	COMP defect (predicted amino-acid change)	Previously published or novel mutation ^a	Differential diagnosis and/or other gene mutation
	A	N	U								
41	1	0	0	UK	PSACH	n/d			No		CHH
42	1	0	0	F	PSACH	n/d			No		SEMD unclassified
43	1	0	0	D	MED	Sporadic	10	c.1096 G>C	p.Gly366Arg	Novel	
44	2	2	0	UK	MED	AD ^b	16	c.1813 G>C	p.Asp605Asn	Novel	
45	1	4	0	UK	MED	Sporadic ^c	11	c.1220 G>T	p.Cys407Phe	Novel	
46	2	1	0	D	MED	AD ^b	10	c.1132 G>T	p.Asp378Tyr	Novel	
47	2	0	0	UK	MED	AD ^b	8	c.827 C>G	p.Pro276Arg	Czarny-Ratajczak <i>et al</i> (2001) ³²	
48	4	1	0	UK	MED	AD ^b	14	c.1665 C>G	p.Asn555Lys	Novel	
49	3	1	0	I	MED	AD ^b	11	c.1154_1156 del	p.Asn386 del	Novel	
50	1	2	0	UK	MED	AD ^b	13	c.1475 A>C	p.Gln492Pro	Novel	
51	1	2	0	D	MED	Sporadic ^c	13	c.1315 G>A	p.Asp439Asn	Novel	
52	2	3	0	UK	MED	AD ^{b,c}	11	c.1195 G>A	p.Asp399Asn	Novel	
53	5	3	0	UK	MED	AD ^b	11	c.1153 G>A	p.Asp385Asn	Mabuchi <i>et al</i> (2003) ²⁶	
54	1	2	0	UK	MED	AD ^b	9	c.929 A>T	p.Asp310Val	Novel	
55	1	2	0	UK	MED	Sporadic ^c	10	c.1102 G>C	p.Gly368Arg	Novel	
56	2	0	0	UK	MED	AD ^b	14	c.1665 C>A	p.Asn555Lys	Novel	
57	4	2	0	UK	MED	AD ^b	11	c.1153 G>A	p.Asp385Asn	Mabuchi <i>et al</i> (2003) ²⁶	
58	1	0	0	UK	MED	n/d	11	c.1153 G>A	p.Asp385Asn	Mabuchi <i>et al</i> (2003) ²⁶	
59	1	0	0	D	MED	n/d	18	c.2153 G>C	p.Arg718Pro	Novel	
60	1	0	0	UK	MED	n/d	13	c.1435 G>C	p.Asp479His	Novel	
61	1	0	0	UK	MED	n/d	13	c.1362 T>G	p.Ser454Arg	Novel	
62	1	1	0	CH	MED	n/d	11	c.1153 G>A	p.Asp385Asn	Mabuchi <i>et al</i> (2003) ²⁶	
63	1	0	0	NL	MED	n/d	11	c.1201 G>A	p.Asp401Asn	Novel	
64	1	0	0	D	MED	Sporadic			No		DTDST
65	2	1	0	UK	MED	AD			No		E134 K in <i>MATN3</i> ³³
66	3	1	0	UK	MED	AD			No		A219D in <i>MATN3</i> ³³
67	1	0	0	B	MED	AR/ Mosaicism			No		R121W in <i>MATN3</i> ³³
68	1	0	0	UK	MED	Sporadic			No		Synovial chondromatosis ASPED
69	1	0	0	UK	MED	n/d			No		
70	1	0	0	UK	MED	n/d			No		
71	1	0	0	D	MED	n/d			No		
72	1	0	0	Aust	MED	Sporadic			No		
73	1	0	0	UK	MED	n/d			No		
74	1	2	0	B	MED	n/d			No		
75	1	0	0	UK	MED	n/d			No		
76	1	0	0	UK	MED	AD?			No		
77	1	0	0	UK	MED	Sporadic			No		
78	1	0	0	UK	MED	n/d			No		
79	1	0	0	UK	MED	n/d			No		
80	2	1	1	UK	MED	AD			No		

Table 2 (Continued)

Family	No. of family members			Country of referral	Diagnosis on referral	Inheritance	Exon	COMP mutation (nucleotide)	COMP defect (predicted amino-acid change)	Previously published or novel mutation ^a	Differential diagnosis and/or other gene mutation
	A	N	U								
81	1	0	0	UK	MED	Sporadic				No	
82	1	0	0	UK	MED	n/d				No	
83	1	0	0	UK	MED	n/d				No	
84	1	2	0	UK	MED	Sporadic				No	
85	1	0	0	UK	MED	n/d				No	
86	1	0	0	B	MED	n/d				No	
87	1	0	0	UK	MED	n/d				No	
88	1	0	0	D	MED	n/d				No	
89	1	0	0	UK	MED	n/d				No	
90	1	0	0	D	MED	n/d				No	
91	1	0	0	Aust	MED	AD?				No	
92	1	0	0	D	MED	n/d				No	
93	2	0	0	B	MED	n/d				No	
94	1	0	0	D	MED	Sporadic				No	
95	1	0	0	UK	MED	n/d				No	
96	2	0	0	UK	MED	AD ^c				No	
97	1	0	0	UK	MED	n/d				No	
98	1	0	0	F	MED	n/d				No	
99	1	0	0	UK	MED	n/d				No	
100	1	0	0	UK	MED	n/d				No	

A: affected; N: not affected; U: unknown.

UK: United Kingdom; B: Belgium; D: Germany; F: France; NL: Netherlands; CH: Switzerland; TR: Turkey; E: Spain; I: Italy; Aust: Australia.

AD: autosomal dominant; AR: autosomal recessive.

^aData from Human Gene Mutation Database (HGMD).²⁵

^bAffected parent and/or other family members carry mutation while unaffected and/or other family members do not have mutation.

^cUnaffected parents and/or other family members do not carry mutation.

n/d: Not determined. ASPED: Trichorhinophalangeal dysplasia and angel-shaped phalangoepiphyseal dysplasia; Brachy C: Brachy-dactyly type C; SEMD-JL: Spondylo-epi-metaphyseal dysplasia with joint laxity, Hall type. Nomenclature in accordance with the current Human Genome Variation Society guidelines (<http://www.hgvs.org>).

congenita (SEDC) and unclassified forms of skeletal dysplasia with radiographic characteristics of spondyloepimetaphyseal dysplasia (SEMD) or spondylometaphyseal dysplasia (SMD). In family 37, a diagnosis of PSACH was thought unlikely but a differential diagnosis could not be suggested, while in family 36 a diagnosis of an unclassified SMD had been suggested on referral, but we were unable to examine the clinical history and radiographs ourselves. This was also the case with the proband in family 40 who was noted to be lacking some features usually associated with PSACH (such as joint laxity), but we were unable to follow this up. Thus, this retrospective analysis of the available clinical and radiographic indicators highlights the difficulty in diagnosing PSACH, the clinical and radiographic overlap that exists between PSACH and various unclassified forms of SEMD and SMD and supports a *COMP* mutation frequency of nearly 100% (31/32) in clinically confirmed cases of PSACH.

Although our detection rate of *COMP* mutations in MED was higher than previously reported (36% compared to 28%), we, nonetheless, reassessed the clinical diagnosis when possible (only two families in total) and a revised diagnosis was suggested in both cases (families 68 and 69). Furthermore, in four families mutations were identified in the other genes known to cause MED such as *DTDST* (patient 64) and *MATN3* (patients 65–67).

In addition to the disease-causing mutations, we also identified three single nucleotide polymorphisms (SNPs); these being synonymous (type III SNP), nonsynonymous (type I SNP) and noncoding (type V SNP), respectively (Table 3). The relatively few polymorphisms in *COMP* contrasts with the other genes involved in the skeletal dysplasias, such as *SLC26A2* (*DTDST*) and the collagen types II, IX and XI genes, which are all highly polymorphic. The paucity of polymorphisms in *COMP* therefore makes it highly likely that any nonsynonymous change identified is likely to be disease-causing, however, care should still be taken when determining if a DNA change is a disease-causing mutation. For example, it was surprising that the type I SNP (N386D) was not disease-causing because it affects a highly conserved residue and mutations at neighbouring residues (D385N and C387G) have been shown to cause MED and PSACH, respectively.

The identification of a causative mutation in families with PSACH or MED not only confirmed their clinical

Table 3 SNPs identified in *COMP*

SNP	Protein change	SNP type	Exon	Allele frequency
c.1156 A>G	Asn386Asp	I	11	0.03
c.1755 G>A	Thr585Thr	III	16	0.05
c.2289 A>G	No change	V	3' UTR	0.005

diagnosis but in seven families provided information that was immediately useful for reproductive decision-making and genetic testing of at-risk family members (Table 4). These follow-on referrals included presymptomatic and prenatal diagnosis, while one family intended to use the information in conjunction with *in vitro* fertilisation for preimplantation diagnosis.

Discussion

The correct diagnosis of many skeletal dysplasias is a time-consuming and complicated process involving the clinical and radiographic evaluation of the proband and other family members.⁷ In many cases, the clinical and radiographic findings are used to determine a differential diagnosis prior to a confirmatory molecular test. To improve this procedure, we have established an accurate and efficient molecular diagnostic protocol for *COMP* gene analysis of patients with PSACH or MED. Over a 3-year period, we screened the *COMP* gene in 100 families with a suspected diagnosis of PSACH or MED and identified disease-causing *COMP* mutations in over half of them (53%). Of the 53 *COMP* mutations identified, 23 (43%) had previously been published (data from Human Gene Mutation Database),²⁵ whereas 30 mutations (57%) were novel to a single family (44% of PSACH and 76% of MED families, respectively).

We identified the recurrent PSACH mutation (p.Asp473 del, often referred to as ΔD469, in exon 13) in 9/32 (28%) mutations, which agrees with the previously published frequency,¹⁸ while in-frame deletions/insertions on the whole represented 15/32 (47%) of the mutations identified in PSACH, the remaining 53% of mutations being missense

Table 4 Type of re-referral and outcome if known

Family	Diagnosis	Request	Outcome
13	PSACH	Preimplantation genetic diagnosis	Unknown
18	PSACH	Suspected diagnosis of PSACH in 14-year-old sister of the proband	Negative for mutation
5	PSACH	Prenatal diagnosis	Negative for mutation
9	PSACH	Predictive testing in the infant son of the proband	Positive for mutation
17	PSACH	Predictive testing in the 8-month-old son of the proband	Positive for mutation
25	PSACH	Predictive testing in the 9-month-old son of the proband	Negative for mutation




Figure 1 Genomic distribution of 53 *COMP* mutations identified patients with pseudoachondroplasia or multiple epiphyseal dysplasia. Note: exon 13 contains the recurrent PSACH mutation p.Asp473 del (often referred to as Δ D469).

mutations. In contrast, only one in-frame deletion (5%) was identified in a patient referred with MED; the remaining mutations were all missense mutations. Furthermore the genomic distribution of mutations also differed between PSACH and MED (Figure 1). While the majority of PSACH mutations were located in exon 13 (50%), only 19% of MED mutations were found in exon 13, whereas the majority (38%) of MED mutations were found in exon 11. This distribution is clearly a reflection of the predominance of in-frame deletions found in PSACH patients. Interestingly, our structured screening strategy meant that a 'level 1 screen' (exons 10 and 13) would on average detect 66% of the *COMP* mutations found in PSACH patients and 33% of the *COMP* mutations found in MED patients. Therefore, by modifying our level 1 screen and targeting exons 10, 13 and 14 in PSACH and 10, 11 and 13 in MED, we would in future be able to identify 85 and 71% of *COMP* mutations in PSACH and MED, respectively.

Our higher than expected detection of *COMP* mutations in MED (36% compared with 28%) may in part be the result of our sensitive screening protocol, which included the use of a DNA sequence analysis package (ie Staden). Alternatively, our referrals were primarily from clinical genetic departments and as such these cases may be representative of the more severe forms of MED and therefore more likely to be caused by *COMP* mutations.

The fact that six families had already proceeded to use their genetic test result to inform reproductive decision-making or facilitate testing for at-risk family members is interesting and shows the clinical utility of genetic testing for these conditions (Table 4). In three of these families (families 9, 17 and 25) predictive testing was performed on infants under the age of 9 months, when it is difficult for the nonexpert to detect the radiographic changes that are indicative of PSACH. In all six families, the diagnosis was PSACH, which probably reflects an increased desire to use

genetic information to direct future decisions in this clinically more severe condition, rather than an increased detection of mutations in the PSACH patient group.

Previous publications have suggested that PSACH results exclusively from *COMP* mutations;^{18,23} however in our cohort of PSACH patients we were only able to identify mutations in 78% of them, which highlights the difficulty in arriving at a differential diagnosis and the important role that molecular diagnosis can play in the diagnostic process. Re-evaluation of the clinical and radiographic indicators suggested a revised diagnosis in most of these cases and indeed mutations were subsequently found in other genes in two of those cases. This successful outcome highlights the need for an integrated diagnostic network for rare diseases when the diagnosis is difficult for the nonexpert. Accurate diagnosis in the skeletal dysplasias and the most cost-effective use of mutation analysis requires a multidisciplinary approach, in particular the integration of clinical diagnostic and radiographic skills with the clinical molecular genetics laboratory. The disparate nature of these conditions necessitates an accurate assessment of the available clinical information to target a molecular analysis to the most likely causative gene. The identification of a disease-causing mutation will then provide essential qualitative information for diagnostic, reproductive and genetic counselling purposes. In addition, the development of a clinical genetic testing service for *COMP* mutation analysis may provide a paradigm for the development of mutation screening services for complex genes. The creation of a screening strategy; refinement of analysis, for example, by screening exon pairs in single amplimers; and the close liaison between clinicians and laboratory scientists to maximise efficiency of mutation detection are consistent with the objectives set out in the recent UK Government White Paper (Our inheritance our future)³⁴ for the screening of complex genes.

Acknowledgements

We sincerely thank our colleagues from the European Skeletal Dysplasia Network (www.ESDN.org) for their help with this project; Valerie Cormier-Daire, Christine Hall, Martine Le Merrer, Geert Mortier, Jurgen Spranger, Andrea Superti-Furga, Sheila Unger, Bernhard Zabel and Andreas Zankl. In addition, we thank David Crauford and Saima Alam for help in recruiting some of the patients used in this study. This work was supported by Health Foundation (formerly the PPP Health Care Medical Trust) and the European Commission (Project Contract Number QLG1-CT-2001-02188). MDB is Wellcome Trust Senior Research Fellow.

References

- Hall CM: International nosology and classification of constitutional disorders of bone (2001). *Am J Med Genet* 2002; 113: 65–77.
- Gustavson KH, Jorulf H: Different types of osteochondrodysplasia in a consecutive series of newborns. *Helv Paediatr Acta* 1975; 30: 307–314.

- 3 Camera G, Mastroiacovo P: Birth prevalence of skeletal dysplasias in the Italian Multicentric Monitoring System for Birth Defects; in: Papadatos CJ, Bartsocas CS (eds): *Skeletal dysplasias*. New York: Alan R. Liss, 1982, pp 441–449.
- 4 Orioli IM, Castilla EE, Barbosa-Neto JG: The birth prevalence rates for the skeletal dysplasias. *J Med Genet* 1986; **23**: 328–332.
- 5 Andersen Jr PE: Prevalence of lethal osteochondrodysplasias in Denmark [see comments]. *Am J Med Genet* 1989; **32**: 484–489.
- 6 Stoll C, Dott B, Roth M-P, Alembik Y: Birth prevalence of skeletal dysplasias. *Clin Genet* 1989; **35**: 88–92.
- 7 Mortier GR: The diagnosis of skeletal dysplasias: a multidisciplinary approach. *Eur J Radiol* 2001; **40**: 161–167.
- 8 Bassett GS: The osteochondrodysplasias; in: Morrissy R, Weinstein SL (eds): *Pediatric orthopedics*. Philadelphia, PA: Lippincott-Raven, 1996, vol 1, pp 203–254.
- 9 Pauli RM, Horton UK, Glinski LP, Reiser CA: Prospective assessment of risks for cervico-medullary compression in infants with achondroplasia. *Am J Hum Genet* 1995; **56**: 732–744.
- 10 Tasker RC, Dundas I, Laverty A, Fletcher M, Lane R, Stocks J: Distinct patterns of respiratory difficulty in young children with achondroplasia: a clinical, sleep and lung function study. *Arch Dis Child* 1998; **79**: 99–108.
- 11 Mogayzel Jr PJ, Carroll JL, Loughlin GM, Hurko O, Francomano CA, Marcus CL: Sleep-disordered breathing in children with achondroplasia. *J Paediatr* 1998; **132**: 667–671.
- 12 Hill V, Sahhar M, Aitken M, Savarirayan R, Metcalfe S: Experiences at the time of diagnosis of parents who have a child with a bone dysplasia resulting in short stature. *Am J Med Genet* 2003; **122A**: 100–107.
- 13 Hunter AG: Some psychological aspects of nonlethal chondrodysplasias: II. Depression and anxiety. *Am J Med Genet* 1998; **78**: 9–12.
- 14 Hunter AG, Bankier A, Rogers JG, Sillence D, Scott Jr CI: Medical complications of achondroplasia: a multicentre patient review. *J Med Genet* 1998; **35**: 705–712.
- 15 Aryanpur J, Hurko O, Francomano C *et al*: Craniocervical decompression in pediatric patients with achondroplasia. *J Neurosurg* 1990; **73**: 375.
- 16 Unger S: A genetic approach to the diagnosis of skeletal dysplasia. *Clin Orthop* 2002; **32**: 32–38.
- 17 Rimoin DL, Rasmussen IM, Briggs MD *et al*: A large family with features of pseudoachondroplasia and multiple epiphyseal dysplasia: exclusion of seven candidate gene loci that encode proteins of the cartilage extracellular matrix. *Hum Genet* 1994; **93**: 236–242.
- 18 Briggs MD, Chapman KL: Pseudoachondroplasia and multiple epiphyseal dysplasia: mutation review, molecular interactions, and genotype to phenotype correlations. *Hum Mutat* 2002; **19**: 465–478.
- 19 Newman B, Donnan D, Briggs MD: Molecular diagnosis is important to confirm suspected pseudoachondroplasia. *J Med Genet* 2000; **37**: 64–65, (letter).
- 20 Bonfield JK, Rada C, Staden R: Automated detection of point mutations using fluorescent sequence trace subtraction. *Nucleic Acids Res* 1998; **26**: 3404–3409.
- 21 Newton G, Weremowicz S, Morton CC *et al*: Characterization of human and mouse cartilage oligomeric matrix protein. *Genomics* 1994; **24**: 435–439.
- 22 Hall CM, Elcioglu NH, Shaw DG: A distinct form of spondyloepimetaphyseal dysplasia with multiple dislocations. *J Med Genet* 1998; **35**: 566–572.
- 23 Cohn DH, King LM, Unger SL: Locus homogeneity in pseudoachondroplasia. *Am J Hum Genet* 2000; **67**: 369.
- 24 Unger SL, King LM, Sobetzko D, Superti-Furga A, Cohn DH: A multiplicity of loci for multiple epiphyseal dysplasia. *Am J Hum Genet* 2000; **67**: 371.
- 25 Stenson PD, Ball EV, Mort M *et al*: Human Gene Mutation Database (HGMD): 2003 update. *Hum Mutat* 2003; **21**: 577–581.
- 26 Mabuchi A, Manabe N, Haga N *et al*: Novel types of COMP mutations and genotype–phenotype association in pseudoachondroplasia and multiple epiphyseal dysplasia. *Hum Genet* 2003; **112**: 84–90.
- 27 Deere M, Sanford T, Ferguson HL, Daniels K, Hecht JT: Identification of twelve mutations in cartilage oligomeric matrix protein (COMP) in patients with pseudoachondroplasia. *Am J Med Genet* 1998; **80**: 510–513.
- 28 Loughlin J, Irvn C, Mustafa Z *et al*: Identification of five novel mutations in cartilage oligomeric matrix protein gene in pseudoachondroplasia and multiple epiphyseal dysplasia [In Process Citation]. *Hum Mutat* 1998; Suppl 1: S10–S17.
- 29 Hecht JT, Nelson LD, Crowder E *et al*: Mutations in exon 17B of cartilage oligomeric matrix protein (COMP) cause pseudoachondroplasia. *Nat Genet* 1995; **10**: 325–329.
- 30 Delot E, Brodie SG, King LM, Wilcox WR, Cohn DH: Physiological and pathological secretion of cartilage oligomeric matrix protein by cells in culture. *J Biol Chem* 1998; **273**: 26692–26697.
- 31 Ikegawa S, Ohashi H, Nishimura G *et al*: Novel and recurrent COMP (cartilage oligomeric matrix protein) mutations in pseudoachondroplasia and multiple epiphyseal dysplasia. *Hum Genet* 1998; **103**: 633–638.
- 32 Czarny-Ratajczak M, Lohiniva J, Rogala P *et al*: A Mutation in COL9A1 Causes multiple epiphyseal dysplasia: further evidence for locus heterogeneity. *Am J Hum Genet* 2001; **69**: 5.
- 33 Jackson GC, Barker FS, Jakkula E *et al*: Missense mutations in the beta strands of the single A-domain of matrilin-3 result in multiple epiphyseal dysplasia. *J Med Genet* 2004; **41**: 52–59.
- 34 Department of Health: Our inheritance, our future – realising the potential of genetics in the NHS; June 2003, (www.dh.gov.uk/PolicyAndGuidance/HealthAndSocialCareTopics/Genetics/) accessed, September 2004.